

Acquired Antibody Responses against *Plasmodium vivax* Infection Vary with Host Genotype for Duffy Antigen Receptor for Chemokines (DARC)

Amanda Maestre¹, Carlos Muskus², Victoria Duque², Olga Agudelo², Pu Liu³, Akihide Takagi³, Francis B. Ntumngia⁴, John H. Adams⁴, Kim Lee Sim⁵, Stephen L. Hoffman⁶, Giampietro Corradin⁷, Ivan D. Velez², Ruobing Wang^{3*}

1 Grupo Salud y Comunidad, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia, **2** Programa de Estudio y Control de Enfermedades Tropicales (PECET), Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia, **3** Seattle Biomedical Research Institute (SBRI), Seattle, Washington, United States of America, **4** University of South Florida, Tampa, Florida, United States of America, **5** Protein Potential LLC., Rockville, Maryland, United States of America, **6** Sanaria, Rockville, Maryland, United States of America, **7** Department of Biochemistry, Université de Lausanne, Lausanne, Switzerland

Abstract

Background: Polymorphism of the Duffy Antigen Receptor for Chemokines (DARC) is associated with susceptibility to and the severity of *Plasmodium vivax* malaria in humans. *P. vivax* uses DARC to invade erythrocytes. Individuals lacking DARC are 'resistant' to *P. vivax* erythrocytic infection. However, susceptibility to *P. vivax* in DARC+ individuals is reported to vary between specific DARC genotypes. We hypothesized that the natural acquisition of antibodies to *P. vivax* blood stages may vary with the host genotype and the level of DARC expression. Furthermore, high parasitemia has been reported to effect the acquisition of immunity against pre-erythrocytic parasites. We investigated the correlation between host DARC genotypes and the frequency and magnitude of antibodies against *P. vivax* erythrocytic stage antigens.

Methodology/Findings: We assessed the frequencies and magnitudes of antibody responses against *P. vivax* and *P. falciparum* sporozoite and erythrocytic antigens in Colombian donors from malaria-endemic regions. The frequency and level of naturally-acquired antibodies against the *P. vivax* erythrocytic antigens merozoite surface protein 1 (PvMSP1) and Duffy binding protein (PvDBP) varied with the host DARC genotypes. Donors with one negative allele (FY*B/FY*Bnull and FY*A/FY*Bnull) were more likely to have anti-PvMSP1 and anti-PvDBP antibodies than those with two positive alleles (FY*B/FY*B and FY*A/FY*B). The lower IgG3 and IgG1 components of the total IgG response may account for the decreased responses to *P. vivax* erythrocytic antigens with FY*A/FY*B and FY*B/FY*B genotypes. No such association was detected with *P. falciparum* erythrocytic antigens, which does not use DARC for erythrocyte invasion.

Conclusion/Significance: Individuals with higher DARC expression, which is associated with higher susceptibility to *P. vivax* infection, exhibited low frequencies and magnitudes of *P. vivax* blood-stage specific antibody responses. This may indicate that one of the primary mechanisms by which *P. vivax* evades host immunity is through DARC indirectly down-regulating humoral responses against erythrocytic invasion and development.

Citation: Maestre A, Muskus C, Duque V, Agudelo O, Liu P, et al. (2010) Acquired Antibody Responses against *Plasmodium vivax* Infection Vary with Host Genotype for Duffy Antigen Receptor for Chemokines (DARC). PLoS ONE 5(7): e11437. doi:10.1371/journal.pone.0011437

Editor: Jörg Hermann Fritz, University of Toronto, Canada

Received: September 13, 2009; **Accepted:** April 4, 2010; **Published:** July 15, 2010

Copyright: © 2010 Maestre et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by NIH R01 grant (AI057592) and Non-Government research support. The funders had no role in study design, data collection and analysis, decision for publication, or preparation of the manuscript.

Competing Interests: Non-Government research support (the commercial funder of this study) express NO competing interest as it relates to employment, consultancy, patents, products in development or marketed products, etc. The authors also confirm that this does NOT alter their adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the PLoS ONE online guide.

* E-mail: ruobing.wang@seattlebiomed.org

Introduction

Malaria remains the most important parasitic infection in the world with almost half a billion clinical cases every year [1]. It is caused by infection with one or more of five species of *Plasmodium* parasites. However, two species, *P. falciparum* and *P. vivax*, are responsible for most of the morbidity and mortality due to malaria [2,3,4,5,6]. *P. vivax* malaria does not attract as much attention from the scientific community, government entities or funding agencies as does the more deadly *P. falciparum* malaria. This is partly because *P. vivax* malaria was in the past erroneously referred

to as 'benign' tertian malaria. But recent studies have revealed that *vivax* malaria can potentially lead to severe debilitating complications and about 2 billion people spread across 3 continents are continuously at risk of the infection [3,4,5,6,7,8]. The discovery and development of novel interventions, most especially vaccines, will depend upon a better understanding of parasite biology and the naturally induced immune response in humans [9,10,11,12].

An important biological difference between *P. vivax* and *P. falciparum* is that only *P. vivax* merozoites use the Duffy (Fy) antigen/receptor for chemokines (DARC) to invade erythrocytes [13,14]. DARC is a glycosylated membrane protein that is

encoded by a gene located on the long arm of chromosome 1 [15,16,17,18,19]. DARC is more abundant on the surface of reticulocytes than on mature erythrocytes and is also expressed on the endothelial surfaces of some organs [17,18]. DARC binds to most inflammatory chemokines and its roles in the immune system include leukocyte activation and recruitment [20,21]. In addition, DARC is associated with protection and susceptibility to a number of other infectious and non-infectious diseases [22,23,24,25], potentially via its elimination of excess toxic chemokines produced during infectious processes and its regulation of leukocyte trafficking [26,27]. Finally, DARC is the essential receptor required for the entry of *P. vivax* into erythrocytes [13].

Genetic polymorphisms have been identified in humans that affect the expression of the Duffy antigen and the susceptibility to blood stage infection by *P. vivax*. Fy+ individuals have 5 common genotypes (FY*A/FY*A, FY*A/FY*B, FY*A/FY*Bnull, FY*B/FY*B and FY*B/FY*Bnull) that produce 3 major phenotypes (Fy a⁺/b⁺, Fy a⁺/b⁻, Fy a⁻/b⁺). Red cells from all Fy+ individuals are susceptible to *P. vivax* infection. People with mutations in the DARC promoter region that abolish DARC expression (FY*Bnull/FY*Bnull or FY*O) exhibit a Duffy-negative phenotype (Fy-) [28,29,30]. Erythrocytes of Fy- individuals cannot be invaded by *P. vivax* merozoites such that Fy- individuals are refractory to *P. vivax* blood stage infection. However, since sporozoite invasion of hepatocytes does not involve DARC, both Fy+ and Fy- individuals are susceptible to infection by sporozoites and develop liver stage parasites. But upon release of liver merozoites into the circulation, only Fy+ individuals develop blood stage infections because the erythrocytes of Fy(-) individuals do not express DARC required for erythrocyte invasion by merozoites.

The requirement for DARC in erythrocytic vivax infection limits the infection to the liver stage in Fy- individuals. However, both humoral and cellular immune responses against *P. vivax* pre-erythrocytic parasites have been reported in Fy- humans [31]. The frequencies of antibody responses to the *P. vivax* circumsporozoite protein have in fact been found to be similar between Fy- and Fy+ groups. Nevertheless, responses against erythrocytic antigens were significantly less frequent among Fy- individuals than in Fy+ individuals since Fy- individuals do not develop erythrocytic infections [31,32].

Naturally acquired antibody and T cell responses play a major role in reducing the risk of infection and in clinical protection against malaria infection [33,34,35]. Blood stage infections in rodent malaria and in human *P. falciparum* infections have been reported to suppress T cell responses against liver stage antigens [36,37,38,39]. However, suppression of blood stage infections can permit development of immune responses against liver stage parasites, as shown by the discovery of two promising *P. falciparum* liver stage antigens using sera from people exposed to *P. falciparum* malaria while under chloroquine prophylaxis that eliminated blood stage parasites [15,40,41]. All these data support the notion that a lower parasite load in the blood may be associated with increased acquired immunity against reinfection and clinical protection.

The development of vaccine(s) and other novel interventions targeted at the control of parasites, especially in this case *P. vivax*, requires a better understanding of naturally-acquired immune response. In previous studies, the cellular and humoral immune responses against vivax antigens among Fy+ donors had been compared to those of Fy- donors [31,32]. However, the Fy+ phenotype is conferred by 5 different genotypes, and the diversity of immune responses to *P. vivax* exposure in humans with different genotypes has not yet been assessed. Since the degree of DARC

expression varies remarkably across different FY genotypes [17], we hypothesized that the acquisition of humoral immunity against the blood stage parasites will also vary with the level of DARC expression. This would be in concurrence with the observation that susceptibility and resistance to the infection varies between specific genotypes [42,43]. Furthermore, functional interaction of the different alleles of DARC with DBP for erythrocytic invasion, and the different signaling characteristics of the different DARC alleles after they have bound the DBP, may also be associated with the load of *P. vivax* parasites in the blood. Finally, as a chemokine receptor, DARC may also be involved in the immunomodulation of innate and acquired immune responses against vivax infection. We therefore embarked on the evaluation of the antibody responses associated with different DARC genotypes.

Results

DARC is required for the blood stage infection of vivax malaria and its level of expression varies with specific genotypes associated with susceptibility and resistance to *P. vivax* erythrocyte infection [42,44,45]. This led us to hypothesize that the acquired antibody responses may also vary with the level of DARC expression. This project is an attempt to increase our knowledge of natural acquired immunity against erythrocytic parasites associated with differential DARC gene expression.

First, we demonstrated differences in the antibody responses to erythrocytic antigens between the Fy+ and Fy- groups. We then demonstrated the potential association of antibody responses with different levels of DARC expression [(A/A or A/B)>(A/Bnull or B/B or B/Bnull)] among Fy+ groups. Finally, we wanted to know if the differential antibody responses were associated with not only stratified DARC expression but also with specific DARC genotypes, since it has been reported that susceptibility to erythrocytic vivax infection was different between FY*A and FY*B genotypes [44]. Therefore, we compared the antibody responses between homozygous and heterozygous FYA or FYB genotypes. As controls, we carried out similar evaluations with *P. falciparum* sporozoite and blood stage antigens, which do not require interaction with DARC. The circumsporozoite protein (CSP) was selected as the representative antigen for the pre-erythrocytic stage as it is the immunodominant surface antigen on the sporozoite [46] and also the most advanced vaccine candidates for both vivax and falciparum malaria [47,48]. Merozoite surface protein 1 (MSP1) was also selected as the representative antigen for the erythrocytic stage because of its expression on the surface of merozoites that invade new red blood cells [49] and its prominence in both vivax and falciparum vaccine development [50,51]. The *P. vivax* Duffy Binding Protein (PvDBP) was identified as the parasite protein that engages DARC present on the surface of red blood cells [52,53] and is also being developed as a vaccine candidate [12].

Distribution of Duffy genotypes

In Colombia and throughout the South American continent, the majority of the clinical cases of malaria are caused by *P. vivax* (~70%), while *P. falciparum* is responsible for the remaining ~30% [54,55]. We recruited 233 donors from the malaria-endemic regions of Apartado and Turbo along the Caribbean coast of Colombia (**Table 1**). All donors who participated in this study had been living in the endemic areas for at least 5 years and had not experienced symptomatic malaria in the previous 12 months. About a quarter of the subjects (26%, n = 60) were Duffy negative (FY*Bnull/FY*Bnull). Among the Duffy positive individuals, the heterozygous FY*A/FY*B genotype was the most common

Table 1. Frequencies of genotypes for Duffy antigen receptor for chemokines (DARC) under the study.

Endemic areas, Colombia	Genotype frequencies of Duffy positive FY+					Total FY+	Total FY–
	FY*A/*A	FY*A/*B	FY*A/*Bnull	FY*B/*B	FY*B/*Bnull		
Turbo (N = 155)	13 (8.4) ^a	26 (16.8)	23 (14.8)	17 (11.0)	24 (15.5)	103 (66.5)	52 (33.5)
Apartado (N = 78)	8 (10.3)	26 (33.3)	7 (9.0)	17 (21.8)	12 (15.4)	70 (89.7)	8 (10.3)
Total (N = 233)	21 (9.0)	52 (22.3)	30 (12.9)	34 (14.6)	36 (15.5)	173 (74.2)	60 (25.8)

^aNumber (%) of individuals expressing the genotype(s).
doi:10.1371/journal.pone.0011437.t001

genotype in these regions (22%, n = 52). The frequencies of the other genotypes in the study population (FY*A/FY*A, FY*A/FY*Bnull, FY*B/FY*B and FY*B/FY*Bnull) were 9, 13, 15, and 15%, respectively (Table 1). The overall prevalence of FY*A and FY*B alleles expressed as homozygous or heterozygous among the entire study population was 44% and 65% respectively. We also recruited 30 donors from Medellin, a non-malaria endemic city in Colombia. These included 5 Fy– (17%) and 25 Fy+ (83%) individuals. Their blood samples were used to standardize the assay protocols and as unexposed controls.

Broad antibody responses against *P. vivax* and *P. falciparum* malaria were induced by natural exposure

We assessed antigen-specific antibody responses by ELISA to each of 3 *P. vivax* and 2 *P. falciparum* antigens in sera from each of the individual donors among different DARC genotypes. There were no detectible anti-malaria antibodies in any of the 30 non-exposed control donors living in the non-endemic area (data not shown). The frequency of antibody responses to parasite antigens among donors living in the malaria endemic areas of Apartado

and Turbo is presented in Figure 1. One hundred thirty-nine donors (60%) had antibodies against at least one of the five *P. vivax* or *P. falciparum* antigens that were tested. Thirty-seven donors (16%) had antibodies against at least one *P. vivax* and one *P. falciparum* antigen (Figure 1A). The majority of these (84%, n = 31) were Duffy positive (Fy+) individuals.

A total of 114 donors (49%) had antibodies against at least one of the *P. vivax* antigens assessed (Figure 1B). Among these, 28 donors (12%) had antibodies against both *P. vivax* sporozoite [circumsporozoite protein (PvCSP)] and erythrocytic antigens [merozoite surface protein 1 (PvMSP1) or Duffy binding protein (PvDBP)]. Fifty-six donors had antibody against PvCSP. However, only 4 individuals had antibodies against all 3 *P. vivax* antigens tested (PvCSP, PvMSP1 and PvDBP), while 4 had antibodies against two erythrocytic antigens (PvMSP1 and PvDBP) but not to the sporozoite antigen PvCSP (Figure 1B).

Antibody responses to *P. falciparum* antigens are presented in Figure 1C. Sixty-four (64) donors (27%) had antibodies against at least one of the two *P. falciparum* antigens tested and 5 donors (2%) had antibodies against both PfCSP and PfMSP1.




Figure 1. Broad antibody responses against malaria were induced by natural exposures in Colombia. We assessed malaria antigen-specific antibody responses in 233 donors living in Caribbean coast town (Apartado and Turbo) of Colombia. One hundred thirty nine (60%) donors had antibodies against at least one of five malaria antigens examined. Numbers represent the responders who had antibodies against both *P. vivax* and/or *P. falciparum* antigens (A), different *P. vivax* antigens, PvCSP, PvMSP1, PvDBP (B), or different *P. falciparum* antigens PfCSP and PfMSP1 (C).
doi:10.1371/journal.pone.0011437.g001

The magnitudes of the antibody responses against each antigen are presented as the average Index of Reactivity (IR). The IR is calculated as the average OD value of each sample at 450 nm divided by the sum of average OD values of negative controls (US donors) and 3 standard deviations. Using this standardized IR calculation, none of the 30 donors from the non-malaria endemic area had detectable antibodies to any of the 5 malaria antigens (data not shown). Among the responders from the malaria endemic responders, the average IR for PvCSP, PvMSP1 and PvDBP were 0.83, 0.82, and 0.64, respectively. Those for PfCSP and PfMSP1 were 0.62 and 0.93, respectively (Table 2).

Antibodies against *P. vivax* pre-erythrocytic antigen are comparable among Fy- and Fy+ donors

About a third of the donors living in malaria-endemic regions of Apartado and Turbo had significant antibodies against PvCSP (n = 80, 34%). The majority of those that had PvCSP antibodies were Fy+ (n = 60, 75%) and the remaining were Fy- (n = 20, 25%). The frequency of responses was however comparable between Fy+ and Fy- (35% and 33%, p = 0.85) (Table 2). The magnitude of responses measured by IR was also similar between Fy+ and Fy- populations (0.88 and 0.79 respectively, p = 0.2996) (Figure 2A).

Antibodies against *P. vivax* erythrocytic antigens differ between Duffy positive and Duffy negative donors

A total of 49 donors (25%) living in the malaria-endemic areas had significant antibodies against PvMSP1. The majority of those with PvMSP1 antibodies (90%) were Fy+ (n = 44). The frequency of the responses was significantly higher in Fy+ (16%) than in Fy- (8%) donors (p = 0.005) (Table 2). The magnitude of the responses (IR distribution) was also significantly different between Fy+ and Fy- donors (p = 0.014) (Figure 2B). Furthermore, of the 185 samples from malaria-endemic regions assessed, only 17 (9%) had antibodies against PvDBP and all were Fy+ donors (17 out of 147 tested, 12%). No Fy- donor from malaria-endemic regions had antibodies against PvDBP. Therefore, both the frequency and magnitude of the responses against PvDBP were significantly different between Fy+ and Fy- donors (p = 0.001 for frequency and p = 0.0396 for IR, respectively) (Table 2 and Figure 2C).

In contrast, the frequencies and magnitudes of antibodies against both *P. falciparum* sporozoite antigen (PfCSP) and erythrocytic antigens (PfMSP1) were comparable among Fy+ and Fy- donors. Only 14% (n = 33) of donors living in malaria-endemic areas had antibodies against PfCSP. There were no significant differences in terms of the frequencies (p = 0.308) and magnitude (p = 0.1694) of the responses between Fy+ and Fy- donors (Table 2 and Figure 2D). Among 36 donors (15%) who had antibodies against PfMSP1, there was also no difference in the frequencies (p = 0.175) and magnitude (p = 0.5265) of the responses (Table 2 and Figure 2E).

Frequency and magnitude of antibodies against *P. vivax* erythrocytic antigens in Duffy positive donors varies with FY genotypes

Among the specific Fy+ genotypes, the frequencies of responses against PvCSP among those with double positive alleles (FY*A/FY*B and FY*B/FY*B) were low compared to their corresponding single negative allele genotypes (FY*A/FY*Bnull, FY*B/FY*Bnull). 37% and 26% compared to 43% and 42%, respectively (Table 2). However, the differences were not statistically significant (Table 2, Figure 3A).

Table 2. Immune recognition of different *P. vivax* and *P. falciparum* stage-specific antigens.

Fy Genotype	Anti-PvCSP			Anti-PvMSP1			Anti-PvDBP			Anti-PfCSP			Anti-PfMSP1		
	IR Mean ± SD	#Pos (%)	P value	IR Mean ± SD	#Pos (%)	P value	IR Mean ± SD	#Pos (%)	P value	IR Mean ± SD	#Pos (%)	P value	IR Mean ± SD	#Pos (%)	P value
A/A	0.68 ± 0.65	4 (19%)	N/A	0.78 ± 0.59	3 (14%)	N/A	0.63 ± 0.25	1 (6%)	N/A	0.69 ± 0.56	4 (19%)	N/A	1.29 ± 0.40	4 (19%)	N/A
A/B	0.94 ± 0.69	19 (37%)		1.16 ± 0.82	13 (25%)		0.67 ± 0.31	2 (4%)		0.68 ± 0.41	11 (21%)		0.94 ± 0.34	10 (19%)	
A/Bnull	1.17 ± 0.75	13 (43%)	0.316	1.45 ± 0.56	13 (43%)	0.086	0.88 ± 0.42	4 (22%)	0.025	0.66 ± 0.47	4 (14%)	0.453	1.14 ± 0.51	7 (23%)	0.659
B/B	0.70 ± 0.53	9 (26%)		0.57 ± 0.43	3 (9%)		0.55 ± 0.21	2 (6%)		0.66 ± 0.48	4 (12%)		0.99 ± 0.27	5 (15%)	
B/Bnull	0.90 ± 0.56	15 (42%)	0.181	1.08 ± 0.58	12 (33%)	0.012	1.04 ± 0.84	8 (27%)	0.022	0.63 ± 0.32	4 (11%)	0.932	0.69 ± 0.25	4 (11%)	0.653
Total Fy+	0.88 ± 0.64	60 (35%)		1.01 ± 0.60	44 (16%)		0.80 ± 0.45	17 (12%)		0.66 ± 0.38	27 (16%)		1.01 ± 0.33	30 (17%)	
Bnull/Bnull	0.79 ± 0.58	20 (33%)	0.850	0.64 ± 0.39	5 (8%)	0.005	0.54 ± 0.18	0 (0%)	0.001	0.57 ± 0.39	6 (10%)	0.308	0.84 ± 0.22	6 (10%)	0.175

Antigen-specific total IgG in sera of the donors living in malaria-endemic regions of Colombia (Apartado and Turbo) were assessed by ELISA against *P. vivax* circumsporozoite protein (PvCSP), blood stage antigens (PvMSP1, PvDBP), *P. falciparum* circumsporozoite protein (PfCSP) and blood stage antigen (PfMSP1). A sample is considered positive if the index of reactivity (IR) is greater or equal to 1. IR is calculated as the average OD of sample divided by the cut-off OD with the cut of OD being the sum of average OD values of US donors (with no prior exposure to malaria) + 3 standard deviations. Listed are the mean and SD of the IR, the number and percentage of positive samples (#Pos (%)). P values were calculated by Chi-squared test. doi:10.1371/journal.pone.0011437.t002




Figure 2. Antibody responses against *P. vivax* erythrocytic antigens are significantly greater in Fy+ than in Fy– individuals. Immune recognition of *P. vivax* sporozoite antigen (A: PvCSP) and blood stage antigens (B: PvMSP1, C: PvDBP), or *P. falciparum* sporozoite antigen (D: PfCSP) and blood stage antigen (E: PfMSP1) by sera of Fy+ and Fy– donors were assessed by ELISA. Values are expressed as Index of Reactivity (IR) that is calculated as test OD divided by cut-off OD. The cut-off OD is the average OD value of US donors (with no prior exposure to malaria)+3 SD. doi:10.1371/journal.pone.0011437.g002

Unlike PvCSP, DARC is required for erythrocytic vivax invasion. We compared the antibodies to blood stage antigens with the stratified DARC expression based on (FY*A/FY*A or FY*A/FY*B)>(FY*A/FY*Bnull, FY*B/FY*Bnull, or FY*B/FY*B) [29]. The antibody responses to PvMSP1 were detected in sera from 16 out of 73 in the high DARC expression group (FY*A/FY*A and FY*A/FY*B) compared to 28 out of 100 in the low DARC expression group (FY*A/FY*Bnull, FY*B/FY*Bnull, or FY*B/FY*B). The difference was not significant between the two groups ($p = 0.364$). However, there were significant differences in the prevalence of antibodies to PvDBP between the high and the low DARC expression groups (3/73 vs. 14/100, respectively) ($p = 0.031$). This may be the first hint that high DARC expression may be associated with low antibody responses to vivax blood stage antigens.

We next wanted to determine which specific genotypes of DARC may be responsible for antibody responses. For PvMSP1, the frequency of the responses was much higher in FY*B/FY*Bnull (12/36, 33%) than in FY*B/FY*B (3/34, 9%) ($p = 0.012$) individuals (Table 2). In addition, the magnitude of the responses was also significantly greater in FY*B/FY*Bnull (IR = 1.08 ± 0.58) than in FY*B/FY*B (IR = 0.57 ± 0.43) ($p = 0.0447$) (Table 2 and Figure 3B). A similar low trend in the responses to PvMSP1 was also observed in FY*A/FY*B compared to that in FY*A/FY*Bnull (25% and 43%, respectively). However, the differences in terms of frequency ($p = 0.086$) and

magnitude ($p = 0.3664$) of the responses in this paired group were not significant (Table 2 and Figure 3B).

For PvDBP, the frequencies of the responses were found obviously higher among those with a single negative FY allele (22% for FY*A/FY*Bnull and 27% for FY*B/FY*Bnull) than in those with corresponding double positive FY alleles (4% for FY*A/FY*B and 6% for FY*B/FY*B) with $p = 0.025$ and 0.022 , respectively (Table 2). However, the magnitudes of the responses are different only between FY*B/FY*B (IR = 0.55 ± 0.21) and FY*B/FY*Bnull (IR = 1.04 ± 0.84) ($p = 0.0047$) (Table 2), but not between FY*A/FY*B and FY*A/FY*Bnull ($p = 0.098$) (Figure 3C).

However, with *P. falciparum* sporozoite (PfCSP) and erythrocytic antigens (PfMSP1), no such trend was observed among the specific Fy+ genotypes (Table 2). The frequencies of the responses against PfCSP in FY*A/FY*B and FY*A/FY*Bnull donors were 21% and 14%, respectively, while those in FY*B/FY*B and FY*B/FY*Bnull were 12% and 11%, respectively (Table 2). There were also no significant differences in the magnitudes of the responses in these paired groups measured by IR distribution ($p = 0.8446$ and 0.4961 , respectively) (Figure 3D). For PfMSP1, the frequencies of recognition by FY*A/FY*B and FY*A/FY*Bnull were 19% and 23% respectively, while those for FY*B/FY*B and FY*B/FY*Bnull were 15% and 11%, respectively (Table 2). The IR distribution was also similar between both groups ($p = 0.5335$ and 0.3092 , respectively) (Figure 3E).




Figure 3. The levels of antibody responses against *P. vivax* erythrocytic antigens differ among different Duffy genotypes. Immune recognition of *P. vivax* sporozoite antigen (A: PvCSP) and blood stage antigens (B: PvMSP1, C: PvDBP), or *P. falciparum* sporozoite antigen (D: PfCSP) and blood stage antigen (E: PfMSP1) by sera of donors with different Duffy genotypes FY*A/FY*B (A/B), FY*A/FY*Bnull (A/Bnull), FY*B/FY*B (B/B) and FY*B/FY*Bnull (B/Bnull). Values are expressed as Index of Reactivity (IR) that is calculated as test OD divided by cut-off OD. The cut-off OD is the average OD value of US donors (with no prior exposure to malaria)+3 SD. The IR of donors with FY*A/FY*B genotype is compared with those of FY*A/FY*Bnull, and FY*B/FY*B with FY*B/FY*Bnull using Student's *t*-test and *p* values <0.05 were considered significant. doi:10.1371/journal.pone.0011437.g003

IgM and IgG subclass profiles in reactivity to *P. vivax* erythrocytic antigens

To search for which subtype(s) of immunoglobulin (Ig) may be responsible for the antibody responses to erythrocytic antigens, we analyzed the IgM and IgG subclasses within 29 Fy+ donors who had high magnitudes of total IgG antibodies against PvMSP1 (17 donors) and/or PvDBP (12 donors) (Figure 4). One hundred percent of donors tested had IgM to PvMSP1, whereas, only 23% of the donors who had IgG to PvDBP had detectable IgM to PvDBP. The difference in frequencies of IgM responses to PvMSP1 versus PvDBP is significant ($p < 0.0004$) (Figure 4A). The majority of Fy+ donors that responded to PvMSP1 had IgG1 (95%). The frequencies of other IgG subclasses to PvMSP1 were at similar levels (IgG2 at 68%, IgG3 at 53%, and IgG4 at 63%, respectively). The dominant subclass IgG to PvDBP was IgG1 (92%), then IgG3 (85%), IgG2 (77%), and IgG4 (46%), respectively (Figure 4A). The magnitude of IgG1 (IR = 11.9 ± 3.37) was also dominating the responses to PvMSP1, and then IgG3 (IR = 2.96 ± 1.07), IgG2 (IR = 1.47 ± 0.15), and IgG4 (IR = 1.45 ± 0.27), respectively (Figure 4B). The magnitude of IgG1 to PvDBP was significantly lower than that to PvMSP1 (IR at 4.3 versus 11.9, $p < 0.0011$). However, there were no

statistically significant differences in terms of the magnitudes of other IgG subclasses between PvDBP and PvMSP1 (Figure 4B).

We further compared the frequencies of the IgG subclasses to PvMSP1 and PvDBP among the different FY genotypes. Significant differences were detected in the frequencies of IgG3 responses to PvMSP1 between FY*A/FY*B and FY*A/FY*Bnull ($p = 0.015$), and of IgG1 to PvDBP between FY*B/FY*B and FY*B/FY*Bnull ($p = 0.035$). There was no additional pattern observed for other IgG subclasses to PvMSP1 and PvDBP (Figure 4C).

Discussion

The lack of DARC among almost all individuals of West African origin has been suggested to be due to natural selection induced by *P. vivax* [56,57]. This idea, however, is controversial and *P. vivax* has been observed in some populations lacking DARC, indicating that the parasite may be able to use other host cell receptors for invasion if DARC is not present [28,58,59].

The presence or absence of DARC has been associated with resistance and susceptibility to a range of infectious and non-infectious diseases [13,14,22,23,24,25]. Individuals that lack DARC (Duffy negative, Fy-) are known to be 'resistant' to *P.*




Figure 4. *P. vivax* erythrocytic antigen specific IgM and IgG subclass profiles among different Duffy genotypes. IgM and IgG subclass among Fy+ donors that had total IgG against PvMSP1 and PvDBP was measured by ELISA to determine the frequencies (A) and magnitude (B) of responses against PvMSP1 and PvDBP. IgM and IgG subclass against PvMSP1 and PvDBP were also compared among donors with different Duffy genotypes (C). Samples are considered positive when the OD reading is > average OD of naïve controls + 3SD for frequency of responses or index of reactivity (IR) is greater than 1 for the magnitude of responses, respectively. doi:10.1371/journal.pone.0011437.g004

vivax erythrocytic infection [13,14]. They are, however, still susceptible to the sporozoite-induced liver stage infection for which DARC is not required. Our earlier study and those of others revealed that humoral and cellular immune responses to *P. vivax* pre-erythrocytic antigens such as CSP are present in Fy− individuals [31,32]. Among Fy+ individuals, however, the influence of each allele on the acquisition of immune response against vivax antigens has yet to be fully explored.

The expression levels of erythroid-specific DARC varied with erythrocyte age and between different Fy+ genotypes [43,60,61]. DARC expression was 2-fold higher in Fy*A/Fy*A homozygotes than in Fy*A/Fy*Anull heterozygotes among people living in Papua New Guinea, and higher DARC expression was associated with the higher prevalence of *P. vivax* infection seen in Fy*A/Fy*A compared to Fy*A/Fy*Anull subjects [43]. This was caused by the significant reduction of the adherence of Duffy binding protein to the erythrocyte in individuals who carried the Fy*A/Fy*Anull allele [60]. Individuals with the Fy*B/Fy*B genotype had a higher risk of *P. vivax* infection than those with Fy*B/Fy*Bnull genotype in malaria-endemic regions of Brazil [44]. Moreover, DARC expression has been found to be lower in the Fy*B/Fy*B than in Fy*A/Fy*A and Fy*A/Fy*B genotypes [61]. Hence, apart from the different levels of Fy expression, the specific qualities and subsequent functions of the DARC upon binding to the *vivax* Duffy binding protein and post invasion of erythrocytes, as well as its role in innate immunity as a receptor for

chemokines may all contribute to the resistance and susceptibility to vivax infection. We were motivated to investigate the influence of different Duffy positive alleles on the acquisition of anti-*P. vivax* immunity among individuals living in malaria-endemic regions.

First, we demonstrated that broad antibody responses were detected by ELISA to both *P. vivax* and *P. falciparum* in individuals living in the two malaria endemic areas in Colombia that we studied (Figure 1). The higher prevalence of recognition of at least one *P. vivax* antigen (44%, n = 103) compared to recognition of the corresponding *P. falciparum* antigen(s) (27%, n = 64) probably reflects the higher level of *P. vivax* transmission in these areas compared to that of *P. falciparum* [62,63]. However, the overall low prevalence of recognition of the individual antigens reflects the relatively low level of malaria transmission in these areas and the fact that our selection criteria excluded individuals with active infections.

The high level of recognition of PvCSP regardless of the presence or absence of DARC had previously been recorded among individuals living on the Pacific coast of Colombia [32] and in Brazil [64]. There was no significant difference in the frequency of antibodies to the sporozoite and liver-stage antigen PvCSP among Fy+ and Fy− individuals ($p = 0.2996$). Since sporozoites do not use DARC to infect hepatocytes, Fy+ and Fy− individuals should be equally susceptible to sporozoite infection [65,66].

To determine whether the acquired antibody responses associated with “natural” protection, we focused our studies on

donors that had developed acquired antibody responses but who had undetectable parasitemia by blood smear at the time of enrollment and no history of malaria symptoms in the past 12 months. Long-lasting antibodies and memory B cell responses in other low malaria transmission endemic areas have also been reported to be associated with naturally acquired protection [35]. As we show in **Table 2**, the antibody responses to PvMSP1 differed significantly between Fy+ and Fy− individuals in both frequency ($p = 0.005$) and magnitude ($p = 0.014$) (**Figure 2B**). This observation is consistent with the requirement for DARC for *P. vivax* erythrocytic infection [31,32]. We suspect that the very few Fy− donors in the current study that did have detectable anti-PvMSP1 antibodies had been transiently exposed to PvMSP1 after the release of merozoites from infected hepatocytes into the blood. These merozoites would have been cleared rapidly from the circulation because they would be unable to invade the Fy− erythrocytes in these individuals.

The major finding in this study was within the Fy+ group (**Table 2 and Figure 2–3**), in which the frequencies and magnitudes of the antibody responses to *P. vivax* erythrocytic antigens were significantly higher in individuals possessing a single negative allele (FY*A/FY*Bnull and FY*B/FY*Bnull) than in double positives (FY*A/FY*B and FY*B/FY*B). This is exactly opposite of the expected level of DARC expression [43,61] and susceptibility to *P. vivax* infection [42,67]. It is known that the elevated DARC expression in double-positive individuals confers a higher risk of *P. vivax* infection in comparison to those with one negative gene (FY*A/FY*Bnull, FY*B/FY*Bnull) [43,44,60,61]. Furthermore, active erythrocytic malaria infections have been reported to induce immune suppression that prevents the host from mounting an effective immune response against the blood stage parasites and other co-infecting agents [38,68,69,70,71,72,73]. This immune suppression ranges from inhibition of dendritic cell maturation [38], to inhibition of the generation of specific CD4 T cells [69] and apoptosis of specific CD4 T cells [73]. Thus, it is likely that the high susceptibility to *P. vivax* blood stage infection and concomitant high *P. vivax* erythrocytic parasite load in FY*A/FY*B and FY*B/FY*B double-positive individuals may contribute to the suppression of antibody responses against erythrocytic antigens when compared with FY*A/FY*Bnull and FY*B/FY*Bnull individuals. The higher antibody levels observed in those with a single negative FY allele may also limit parasite load during subsequent infections that may in turn reduce or prevent the immune suppression induced by erythrocytic parasites. Finally, based on DARC's role as a sink for excess pro-inflammatory cytokines [74], high levels of DARC expression in FY double-positives may reduce the surplus of pro-inflammatory cytokines and curb the severity of symptoms; alternatively, DARC may down-regulate the immune responses that control the erythrocytic parasitemia.

This difference in immune recognition between FY*A/FY*B and FY*B/FY*B individuals and FY*A/FY*Bnull and FY*B/FY*Bnull individuals observed with PvMSP1 was confirmed with a second *P. vivax* blood stage antigen, PvDBP, which is involved in *P. vivax* erythrocytic invasion. Our observations that the antibody responses to two *P. vivax* blood stage antigens are higher in single positive than in double-positive individuals leads us to speculate that immune responses to multiple erythrocytic antigens in hosts with low parasite load could act synergistically against erythrocytic parasite invasion and development, providing clinical protection against subsequent reinfection.

In order to determine whether the differential frequencies of recognition to blood versus sporozoite antigens by FY genotypes were restricted to *P. vivax*, we investigated the recognition of PfCSP

and PfMSP1 in the same study population (**Table 2, Figures 2 and 3**). As expected, no such variation in antibody response against *P. falciparum* antigens with FY genotype was observed.

Finally, we wanted to know whether any specific Ig subtypes are responsible for the naturally acquired antibodies that are associated with individual DARC genotypes. IgM responses to malaria are more likely to be detected early after infection and are expected to switch from the IgM isotype to the cytophilic isotypes IgG1 and/or IgG3, a switch that has been associated with clinical control of erythrocytic parasites [75,76]. In some endemic areas the IgG1 response to PvMSP1 is higher, whereas in other areas the IgG3 response dominates [77]. In this study, strong IgM and IgG responses to PvMSP1 were detected in the same Fy+ individuals (**Figure 4**), indicating that the IgM response did not compromise the induction and development of IgG1 and IgG3 responses to this antigen. The magnitude of IgG1 response to PvMSP1 was 3 times greater than the IgG1 response to PvDBP. However, the frequency of IgG3 responses to PvMSP1 was significantly lower in FY*A/FY*B than in FY*A/FY*Bnull ($p = 0.015$) individuals, as were the IgG1 responses to PvDBP in FY*B/FY*B compared to FY*B/FY*Bnull individuals ($p = 0.035$). Therefore, the lower IgG3 and IgG1 components of the total IgG response may account for the decreased responses to *P. vivax* erythrocytic antigens in humans with the double positive FY*A/FY*B and FY*B/FY*B genotypes, respectively (**Figure 4C**). However, the immune mechanism by which differential DARC expression manipulates the specific IgM and IgG subclass profiles associated with clinical protection need to be determined.

In summary, we observed that frequency and magnitude of antibodies specific for *P. vivax* erythrocytic antigens varied with the host DARC genotype. Donors with genotypes associated with higher levels of DARC expression and higher susceptibility to *P. vivax* infection were found to have lesser frequencies and lower magnitudes of specific antibodies against PvMSP1 and PvDBP. IgG3 and IgG1 may account for the decreased responses to *P. vivax* erythrocytic antigens in humans with FY*A/FY*B or FY*B/FY*B genotypes. This supports the notion that one of the primary mechanisms by which *P. vivax* evades host immunity is through DARC indirectly down-regulating humoral responses against erythrocytic invasion and development. These results represent an important advance in our understanding of blood-stage immunity to *P. vivax* that will inform the rational design and development of effective vaccines to control *P. vivax* malaria.

Materials and Methods

Study populations

Subjects were recruited from two malaria-endemic cities of Turbo (8°5'42"N, 76°44'123"W) and Apartado (7°52'40"N, 76°37'44"W) both of which are on the Caribbean coast of Colombia, South America. Their inhabitants are mainly a mixture of indigenous, Hispanic and African backgrounds. Banana cultivation is the major source of income. They both have high migration rates, and malaria transmission is perennial and unstable, with a mean of 10 infectious bites per 1,000 people. During the 2004 to 2008 period, the means of annual *P. vivax* infectious bites are 323 in Turbo and 84 in Apartado per 1,000 inhabitants. *P. falciparum* is less frequent in these two cities during the same period (mean annual infectious bites: Turbo = 44, Apartado = 11) (personal communication with local health authorities) [62,63,78]. The causes of malaria infections in these two areas are comparable; 72% vivax, 28% falciparum and only 0.11% with mixed infection. All the subjects were above 18 years old and were voluntarily recruited. The purpose of the study was

explained to each subject, after which they signed the consent form to participate in the study. Only subjects who had long been residing in the study area for more than 5 years and have no symptoms of malaria within the past year were enlisted. Subjects included in the study were only those with no detectable *P. vivax* or *P. falciparum* parasites in blood smears on the day of sample collection. A total of 233 subjects were enrolled from malaria-endemic areas of Turbo (n = 155) and Apartado (n = 78) (Table 1). For malaria infection naïve controls with specific DARC genotypes, 30 subjects were recruited from Medellín, where there is no malaria transmission. Additional eight adult US donors who had no previous history of malaria or trip to malaria-endemic region were also used as ELISA assay control. Whole blood samples were obtained for Duffy genotyping and the separated sera were used for anti-malaria antibody screening. The study protocol and consent forms were approved by the Ethics committee for research in humans of Sede de Investigación Universitaria (CBEIH-SIU), Universidad de Antioquia (Medellín, Colombia) and Western Institute Review Board (WIRB), USA.

Duffy genotyping

Genomic DNAs from the peripheral blood of all donors were purified using the QIAamp kit (Qiagen), and the quality was assessed in 1.5% agarose gel. PCR was performed to amplify 1000 bp using the following primers: P1, 5'CCTTTTTCCTGAGTGTAGT3' (sense) and P2, 5'GCAGAGCTGC-CAGCGGAAGA3' (antisense) as described previously (68). The PCR conditions were: 95°C 4 min, 35 cycles of 1 min at 94°C, 1 min at 58°C, and 1 min at 58°C, and final 10 min at 72°C. PCR products were purified using Qiagen kit (Valencia, CA) for sequence analysis. Primers P1, P2, or P38 (5'AGGCCTTGTC-CAGGCAGTG3') (68) were used for sequencing reactions. A single nucleotide substitution (T46C) at the promoter region abolishes the expression of the DARC in erythroid tissues (Fy⁻, genotype FY*Bnull/FY*Bnull, phenotype Fya⁻b⁻). A single nucleotide substitution (G131A) at the exon region of DARC determines the allele specificity among Duffy positive donors (Fy⁺).

Recombinant antigens

The recombinant *P. vivax* circumsporozoite protein (PvCSP) that includes the amino terminus repeat region (3X repeat 1 and 3X repeat 2), and carboxyl terminus was provided by Dr. KL Sim (Protein Potential LLC, MD). Recombinant *P. vivax* MSP1 corresponding to MSP1 *P. falciparum* merozoite surface protein 1 (PfMSP1₁₉) and *P. falciparum* MSP1 were obtained from MR4, VA. Recombinant *P. vivax* Duffy Binding Protein (PvDBP) corresponding to region II of the protein was kindly provided by J.H Adams (University of South Florida, Tampa, FL) and *P. falciparum* CSP long synthetic peptide (LSP) corresponding to the amino acid 282–

383 of the C-terminal region was obtained from Dr. G. Corradin (University of Lausanne, Switzerland) [79].

Evaluation of antibody responses

Enzyme Linked Immunosorbent Assay (ELISA) was performed in 96 well flat-bottom-plates (Nunc-Immuno Module, USA). Wells were coated with recombinant proteins PvCSP, PvMSP1 or PfMSP1 at 2.5 µg/mL (PvDBP at 2 µg/mL, PfCSP LSP at 1 µg/mL) in 50 µl of PBS buffer (pH 7.4) and incubated overnight at 4°C. The plates were washed with 200 µl of wash buffer (0.05% Tween-20 in PBS) using Bio-TEK Washer (ELx405) and then blocked with 200 µl of blocking buffer (5% nonfat dry milk in PBS) for 1 hour at room temperature (RT). Fifty microliters (50µl) of 1:50 serum dilutions were added to the coated wells and then incubated for 2 hours at room temperature. After another washing, 50 µl of HRP-labeled goat anti-human IgG (H+L) at 1:4000 in 2.5% milk PBS-Tween-20 was added and the plates were kept at room temperature for 1 hour. For assessment of IgM and IgG1-4 subtypes, the HRP-labeled mouse anti-human antibodies were used at 1:1000 following the manufacturer's instruction (Southern Biotech, Birmingham, AL, USA). They were later developed with tetramethylbenzidine (TMB) substrate (Sigma-Aldrich) and the OD was measured at 450 nm with ELISA Autoreader MR5000 (Dynatech, Chantilly, CA). All the assays were performed in triplicates and repeated twice. The antibody recognition by individual sera is expressed as Index of Reactivity (IR) that is test OD reading divided by cut-off OD. The cut-off OD is calculated as the average OD reading of negative control donors (US donors with no prior exposure to malaria)+3 standard deviations. A sample is considered positive when the IR value is ≥1.

Statistical analysis

Statistical analyses were performed using Graphpad prism 5. Differences in the means were assessed using Student's *t*-test and Chi-squared test. *P* values <0.05 were considered significant.

Acknowledgments

We thank the volunteers, without whom this study could not have been possible. We also thank Malcolm J. Gardner for revision of the manuscript, and Larry Yunker for revision of the figures in the manuscript.

Author Contributions

Conceived and designed the experiments: AM CM IDV RW. Performed the experiments: AM CM VD OA PL AT RW. Analyzed the data: CM PL AT RW. Contributed reagents/materials/analysis tools: FBN JHA KLS SLH GC. Wrote the paper: AM CM RW. Coordinated field and laboratory studies: RW. Coordinated field studies: AM CM IDV.

References

- Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, et al. (2008) The limits and intensity of *Plasmodium falciparum* transmission: implications for malaria control and elimination worldwide. *PLoS Med* 5: e38.
- Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI (2005) The global distribution of clinical episodes of *Plasmodium falciparum* malaria. *Nature* 434: 214–217.
- Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, et al. (2008) *Plasmodium vivax* and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. *PLoS Med* 5: e127.
- Mendis K, Sina BJ, Marchesini P, Carter R (2001) The neglected burden of *Plasmodium vivax* malaria. *Am J Trop Med Hyg* 64: 97–106.
- Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, et al. (2008) Multidrug-resistant *Plasmodium vivax* associated with severe and fatal malaria: a prospective study in Papua, Indonesia. *PLoS Med* 5: e128.
- Kumar S, Melzer M, Dodds P, Watson J, Ord R (2007) *P. vivax* malaria complicated by shock and ARDS. *Scand J Infect Dis* 39: 255–256.
- Baird JK (2007) Neglect of *Plasmodium vivax* malaria. *Trends Parasitol* 23: 533–539.
- Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, et al. (2007) *Vivax* malaria: neglected and not benign. *Am J Trop Med Hyg* 77: 79–87.
- Chitnis CE, Sharma A (2008) Targeting the *Plasmodium vivax* Duffy-binding protein. *Trends Parasitol* 24: 29–34.
- Galinski MR, Barnwell JW (2008) *Plasmodium vivax*: who cares? *Malar J* 7 Suppl 1: S9.
- Herrera S, Corradin G, Arevalo-Herrera M (2007) An update on the search for a *Plasmodium vivax* vaccine. *Trends Parasitol* 23: 122–128.
- Moreno A, Caro-Aguilar I, Yazdani SS, Shakri AR, Lapp S, et al. (2008) Preclinical assessment of the receptor-binding domain of *Plasmodium vivax* Duffy-binding protein as a vaccine candidate in rhesus macaques. *Vaccine* 26: 4338–4344.
- Miller LH, Mason SJ, Clyde DF, McGinniss MH (1976) The resistance factor to *Plasmodium vivax* in blacks. The Duffy-blood-group genotype, FyFy. *N Engl J Med* 295: 302–304.

14. Gelpi AP, King MC (1976) Duffy blood group and malaria. *Science* 191: 1284.
15. Gruner AC, Snounou G, Brahimi K, Letourneur F, Renia L, et al. (2003) Pre-erythrocytic antigens of *Plasmodium falciparum*: from rags to riches? *Trends Parasitol* 19: 74–78.
16. Donahue RP, Bias WB, Renwick JH, McKusick VA (1968) Probable assignment of the Duffy blood group locus to chromosome 1 in man. *Proc Natl Acad Sci U S A* 61: 949–955.
17. Dracopoli NC, O'Connell P, Elser TI, Lalouel JM, White RL, et al. (1991) The CEPH consortium linkage map of human chromosome 1. *Genomics* 9: 686–700.
18. Forabosco P, Collins A, Morton NE (1995) Integration of gene maps: updating chromosome 1. *Ann Hum Genet* 59: 291–305.
19. Mathew S, Chaudhuri A, Murty VV, Pogo AO (1994) Confirmation of Duffy blood group antigen locus (FY) at 1q22->q23 by fluorescence in situ hybridization. *Cytogenet Cell Genet* 67: 68.
20. Horne K, Woolley IJ (2009) Shedding light on DARC: the role of the Duffy antigen/receptor for chemokines in inflammation, infection and malignancy. *Inflamm Res* 58: 431–435.
21. Rossi D, Zlotnik A (2000) The biology of chemokines and their receptors. *Annu Rev Immunol* 18: 217–242.
22. Reich D, Nalls MA, Kao WH, Akyzbekova EL, Tandon A, et al. (2009) Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. *PLoS Genet* 5: e1000360.
23. Zijlstra A, Quigley JP (2006) The DARC side of metastasis: shining a light on KAI1-mediated metastasis suppression in the vascular tunnel. *Cancer Cell* 10: 177–178.
24. Vergara C, Tsai YJ, Grant AV, Rafals N, Gao L, et al. (2008) Gene encoding Duffy antigen/receptor for chemokines is associated with asthma and IgE in three populations. *Am J Respir Crit Care Med* 178: 1017–1022.
25. He W, Neil S, Kulkarni H, Wright E, Agan BK, et al. (2008) Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. *Cell Host Microbe* 4: 52–62.
26. Darbonne WC, Rice GC, Mohler MA, Apple T, Hebert CA, et al. (1991) Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin. *J Clin Invest* 88: 1362–1369.
27. Middleton J, Neil S, Wintle J, Clark-Lewis I, Moore H, et al. (1997) Transcytosis and surface presentation of IL-8 by venular endothelial cells. *Cell* 91: 385–395.
28. Hamblin MT, Thompson EE, Di Rienzo A (2002) Complex signatures of natural selection at the Duffy blood group locus. *Am J Hum Genet* 70: 369–383.
29. Pogo AO, Chaudhuri A (2000) The Duffy protein: a malarial and chemokine receptor. *Semin Hematol* 37: 122–129.
30. Tournamille C, Colin Y, Cartron JP, Le Van Kim C (1995) Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. *Nat Genet* 10: 224–228.
31. Wang R, Arevalo-Herrera M, Gardner MJ, Bonelo A, Carlton JM, et al. (2005) Immune responses to *Plasmodium vivax* pre-erythrocytic stage antigens in naturally exposed Duffy-negative humans: a potential model for identification of liver-stage antigens. *Eur J Immunol* 35: 1859–1868.
32. Herrera S, Gomez A, Vera O, Vergara J, Valderrama-Aguirre A, et al. (2005) Antibody response to *Plasmodium vivax* antigens in Fy-negative individuals from the Colombian Pacific coast. *Am J Trop Med Hyg* 73: 44–49.
33. Barbedo MB, Ricci R, Jimenez MC, Cunha MG, Yazdani SS, et al. (2007) Comparative recognition by human IgG antibodies of recombinant proteins representing three asexual erythrocytic stage vaccine candidates of *Plasmodium vivax*. *Mem Inst Oswaldo Cruz* 102: 335–339.
34. Nogueira PA, Alves FP, Fernandez-Becerra C, Pein O, Santos NR, et al. (2006) A reduced risk of infection with *Plasmodium vivax* and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1. *Infect Immun* 74: 2726–2733.
35. Wipasa J, Suphavitai C, Okell LC, Cook J, Corran PH, et al. (2010) Long-lived antibody and B Cell memory responses to the human malaria parasites, *Plasmodium falciparum* and *Plasmodium vivax*. *PLoS Pathog* 6: e1000770.
36. Oceana-Morgner C, Mota MM, Rodriguez A (2003) Malaria blood stage suppression of liver stage immunity by dendritic cells. *J Exp Med* 197: 143–151.
37. Orjih AU, Nussenzweig RS (1979) *Plasmodium berghei*: suppression of antibody response to sporozoite stage by acute blood stage infection. *Clin Exp Immunol* 38: 1–8.
38. Urban BC, Ferguson DJ, Pain A, Willcox N, Plebanski M, et al. (1999) *Plasmodium falciparum*-infected erythrocytes modulate the maturation of dendritic cells. *Nature* 400: 73–77.
39. Urban BC, Willcox N, Roberts DJ (2001) A role for CD36 in the regulation of dendritic cell function. *Proc Natl Acad Sci U S A* 98: 8750–8755.
40. Guerin-Marchand C, Druilhe P, Galey B, Londono A, Patarapotikul J, et al. (1987) A liver-stage-specific antigen of *Plasmodium falciparum* characterized by gene cloning. *Nature* 329: 164–167.
41. Marchand C, Druilhe P (1990) How to select *Plasmodium falciparum* pre-erythrocytic antigens in an expression library without defined probe. *Bull World Health Organ* 68: 158–164.
42. Kaschagen IJ, Mueller I, Kiniboro B, Bockarie MJ, Reeder JC, et al. (2007) Reduced *Plasmodium vivax* erythrocyte infection in PNG Duffy-negative heterozygotes. *PLoS One* 2: e336.
43. Zimmerman PA, Woolley I, Masinde GL, Miller SM, McNamara DT, et al. (1999) Emergence of FY*(A)null in a *Plasmodium vivax*-endemic region of Papua New Guinea. *Proc Natl Acad Sci U S A* 96: 13973–13977.
44. Cavasini CE, de Mattos LC, Couto AA, Couto VS, Gollino Y, et al. (2007) Duffy blood group gene polymorphisms among malaria vivax patients in four areas of the Brazilian Amazon region. *Malar J* 6: 167.
45. Kaschagen IJ, Mueller I, McNamara DT, Bockarie MJ, Kiniboro B, et al. (2006) Changing patterns of *Plasmodium* blood-stage infections in the wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. *Am J Trop Med Hyg* 75: 588–596.
46. Dame JB, Williams JL, McCutchan TF, Weber JL, Wirtz RA, et al. (1984) Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite *Plasmodium falciparum*. *Science* 225: 593–599.
47. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, et al. (2008) Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. *N Engl J Med* 359: 2521–2532.
48. Herrera S, Bonelo A, Perlaza BL, Fernandez OL, Victoria L, et al. (2005) Safety and elicitation of humoral and cellular responses in Colombian malaria-naïve volunteers by a *Plasmodium vivax* circumsporozoite protein-derived synthetic vaccine. *Am J Trop Med Hyg* 73: 3–9.
49. Lyon JA, Haynes JD, Diggs CL, Chulay JD, Haidaris CG, et al. (1987) Monoclonal antibody characterization of the 195-kilodalton major surface glycoprotein of *Plasmodium falciparum* malaria schizonts and merozoites: identification of additional processed products and a serotype-restricted repetitive epitope. *J Immunol* 138: 895–901.
50. Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, et al. (2005) The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of *Plasmodium falciparum* strain FVO expressed in *Escherichia coli* protects *Aotus nancymai* against challenge with homologous erythrocytic-stage parasites. *Infect Immun* 73: 287–297.
51. Valderrama-Aguirre A, Quintero G, Gomez A, Castellanos A, Perez Y, et al. (2005) Antigenicity, immunogenicity, and protective efficacy of *Plasmodium vivax* MSP1 PV200: a potential malaria vaccine subunit. *Am J Trop Med Hyg* 73: 16–24.
52. Chitnis CE, Miller LH (1994) Identification of the erythrocyte binding domains of *Plasmodium vivax* and *Plasmodium knowlesi* proteins involved in erythrocyte invasion. *J Exp Med* 180: 497–506.
53. Wertheimer SP, Barnwell JW (1989) *Plasmodium vivax*: interaction with the human Duffy blood group glycoprotein: identification of a parasite receptor-like protein. *Experimental Parasitology* 69: 340–350.
54. PAHO (2003) informe de la situacion de los programas de malaria en las Americas. CD44/INF/ 3.
55. Brown GV, Moorthy VS, Reed Z, Mendis K, Arevalo-Herrera M, et al. (2009) Priorities in research and development of vaccines against *Plasmodium vivax* malaria. *Vaccine* 27: 7228–7235.
56. Hamblin MT, Di Rienzo A (2000) Detection of the signature of natural selection in humans: evidence from the Duffy blood group locus. *Am J Hum Genet* 66: 1669–1679.
57. Smith MT (1993) Genetic adaptation in Harrison D. A. *Human Adaptation*. Oxford, England: Oxford University Press.
58. Livingstone FB (1984) The Duffy blood groups, vivax malaria, and malaria selection in human populations: a review. *Hum Biol* 56: 413–425.
59. Menard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, et al. (2010) *Plasmodium vivax* clinical malaria is commonly observed in Duffy-negative Malagasy people. *Proc Natl Acad Sci U S A*.
60. Michon P, Woolley I, Wood EM, Kastens W, Zimmerman PA, et al. (2001) Duffy-null promoter heterozygosity reduces DARC expression and abrogates adhesion of the *P. vivax* ligand required for blood-stage infection. *FEBS Lett* 495: 111–114.
61. Woolley IJ, Hotmire KA, Sramkoski RM, Zimmerman PA, Kazura JW (2000) Differential expression of the duffy antigen receptor for chemokines according to RBC age and FY genotype. *Transfusion* 40: 949–953.
62. Carmona-Fonseca J (2003) La malaria en Colombia, Antioquia y las zonas de Uraba y Bajo Cauca: panorama para interpretar la falla terapeutica antimalarica parte 1. *Latreia* 16: 34–53.
63. Carmona-Fonseca J (2004) La malaria en Colombia, Antioquia y las zonas de Uraba y Bajo Cauca: panorama para interpretar la falla terapeutica antimalarica parte 2. *Latreia* 17: 34–53.
64. Oliveira-Ferreira J, Pratt-Riccio LR, Arruda M, Santos F, Ribeiro CT, et al. (2004) HLA class II and antibody responses to circumsporozoite protein repeats of *P. vivax* (VK210, VK247 and *P. vivax*-like) in individuals naturally exposed to malaria. *Acta Trop* 92: 63–69.
65. Silvie O, Rubinstein E, Franetich JF, Prenant M, Belnoue E, et al. (2003) Hepatocyte CD81 is required for *Plasmodium falciparum* and *Plasmodium yoelii* sporozoite infectivity. *Nat Med* 9: 93–96.
66. Yalaoui S, Huby T, Franetich JF, Gego A, Rametti A, et al. (2008) Scavenger receptor BI boosts hepatocyte permissiveness to *Plasmodium* infection. *Cell Host Microbe* 4: 283–292.
67. Cavasini CE, De Mattos LC, Alves RT, Couto AA, Calvosa VS, et al. (2006) Frequencies of ABO, MNs, and Duffy phenotypes among blood donors and malaria patients from four Brazilian Amazon areas. *Hum Biol* 78: 215–219.
68. Greenwood BM, Bradley-Moore AM, Bryceson AD, Palit A (1972) Immunosuppression in children with malaria. *Lancet* 1: 169–172.
69. Kalmbach Y, Boldt AB, Mordmuller B, Kombila M, Grobusch MP, et al. (2009) Reduced CD3/TCR complex expression leads to immunosuppression during *Plasmodium falciparum* malaria. *Parasitol Res* 104: 575–582.

70. Kemp K, Akanmori BD, Adabayeri V, Goka BQ, Kurtzhals JA, et al. (2002) Cytokine production and apoptosis among T cells from patients under treatment for *Plasmodium falciparum* malaria. *Clin Exp Immunol* 127: 151–157.
71. Kremsner PG, Zotter GM, Feldmeier H, Graninger W, Rocha RM, et al. (1990) Immune response in patients during and after *Plasmodium falciparum* infection. *J Infect Dis* 161: 1025–1028.
72. Riley E, Greenwood B (1990) Measuring cellular immune responses to malaria antigens in endemic populations: epidemiological, parasitological and physiological factors which influence in vitro assays. *Immunol Lett* 25: 221–229.
73. Wipasa J, Xu H, Stowers A, Good MF (2001) Apoptotic deletion of Th cells specific for the 19-kDa carboxyl-terminal fragment of merozoite surface protein 1 during malaria infection. *J Immunol* 167: 3903–3909.
74. Gardner L, Patterson AM, Ashton BA, Stone MA, Middleton J (2004) The human Duffy antigen binds selected inflammatory but not homeostatic chemokines. *Biochem Biophys Res Commun* 321: 306–312.
75. Jafarshad A, Dziegiel MH, Lundquist R, Nielsen LK, Singh S, et al. (2007) A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcγRII and FcγRIII. *J Immunol* 178: 3099–3106.
76. Wickramaratche T, Illeperuma RJ, Perera L, Bandara S, Holm I, et al. (2007) Comparison of naturally acquired antibody responses against the C-terminal processing products of *Plasmodium vivax* Merozoite Surface Protein-1 under low transmission and unstable malaria conditions in Sri Lanka. *Int J Parasitol* 37: 199–208.
77. Fernandez-Becerra C, Sanz S, Brucet M, Stanisic DI, Alves FP, et al. (2010) Naturally-acquired humoral immune responses against the N- and C-termini of the *Plasmodium vivax* MSP1 protein in endemic regions of Brazil and Papua New Guinea using a multiplex assay. *Malar J* 9: 29.
78. Blair S, Carmona-Fonseca J, Pimeros JG, Rios A, Alvarez T, et al. (2006) Therapeutic efficacy test in malaria *falciparum* in Antioquia, Colombia. *Malar J* 5: 14.
79. Lopez JA, Weilenman C, Audran R, Roggero MA, Bonelo A, et al. (2001) A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies. *Eur J Immunol* 31: 1989–1998.